On February 22, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco""the company’, Hong Kong Stock Exchange stock code: 01541.HK) reported that it will present single-agent data of the IMM0306 Phase I and IMM27M Phase I clinical trials and preclinical data of IMM5605 in the form of poster presentations at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper) (AACR 2024) Annual Meeting hold in San Diego, USA, April 5-10 (Press release, ImmuneOnco Biopharma, FEB 22, 2024, View Source [SID1234655696]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Founder and chairman of ImmuneOnco Dr. Tian, Wenzhi said:
"The AACR (Free AACR Whitepaper) Annual Meeting is one of the largest international academic events in the field of cancer in the world, covering comprehensive research on the etiology and treatment of cancer. The results we presented at AACR (Free AACR Whitepaper) 2024 will help inform the industry of the latest clinical data from IMM0306, IMM27M and IMM5605 preclinical studies. We are excited to have the opportunity to share these data with our oncology peers and look forward to further clinical data releases for these products."
Chief Medical Officer/Senior Vice President of ImmuneOnco Dr. Lu said:
The research results of a total of three projects, IMM0306, IMM27M and IMM5605, have been recognized and affirmed by this year’s AACR (Free AACR Whitepaper). IMM0306 has entered Phase II clinical trials in multiple NHL indications, including monotherapy and combination with lenalidomide. In phase I Clinical trial of IMM27M, data showed favorable clinical efficacy and good safety in tumor types including relapsed and refractory breast cancer and melanoma and RP2D was determined, We look forward to rapidly advancing the clinical development of IMM0306, IMM27M and IMM5605 products, bringing new treatment options to the treatment of cancer patients and addressing unmet clinical needs."